Clarifying which of the CD94 -NKG2A or C heterodimers are expressed on T-LGL populations may reveal the underlying regulatory mechanisms and their functional significance in IBM along with other autoimmune disorders and ultimately lead to the identification of useful prognostic biomarkers and the development of novel therapeutic interventions. Here, KLRC1 is linked to inclusion body myositis.